These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Varicella-zoster vaccine. Senanayake SN N Engl J Med; 2007 Jul; 357(1):89-90. PubMed ID: 17615639 [No Abstract] [Full Text] [Related]
7. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). Harpaz R; Ortega-Sanchez IR; Seward JF; MMWR Recomm Rep; 2008 Jun; 57(RR-5):1-30; quiz CE2-4. PubMed ID: 18528318 [TBL] [Abstract][Full Text] [Related]
8. Vaccination against herpes zoster in developed countries: state of the evidence. Drolet M; Oxman MN; Levin MJ; Schmader KE; Johnson RW; Patrick D; Mansi JA; Brisson M Hum Vaccin Immunother; 2013 May; 9(5):1177-84. PubMed ID: 23324598 [TBL] [Abstract][Full Text] [Related]
9. Modeling the impact of combined vaccination programs against varicella and herpes zoster in Norway. Marchetti S; Guzzetta G; Flem E; Mirinaviciute G; Scalia Tomba G; Manfredi P Vaccine; 2018 Feb; 36(8):1116-1125. PubMed ID: 29366704 [TBL] [Abstract][Full Text] [Related]
10. A 70-year-old woman with shingles: review of herpes zoster. Whitley RJ JAMA; 2009 Jul; 302(1):73-80. PubMed ID: 19491172 [TBL] [Abstract][Full Text] [Related]
11. Current and future effects of varicella and herpes zoster vaccination in Germany - Insights from a mathematical model in a country with universal varicella vaccination. Horn J; Karch A; Damm O; Kretzschmar ME; Siedler A; Ultsch B; Weidemann F; Wichmann O; Hengel H; Greiner W; Mikolajczyk RT Hum Vaccin Immunother; 2016 Jul; 12(7):1766-76. PubMed ID: 26835890 [TBL] [Abstract][Full Text] [Related]
16. Zoster vaccine: current status and future prospects. Oxman MN Clin Infect Dis; 2010 Jul; 51(2):197-213. PubMed ID: 20550454 [TBL] [Abstract][Full Text] [Related]
17. [Chickenpox and shingles: one virus, two diseases and current vaccination recommendations in Switzerland]. Eckert N; Masserey Spicher V Ther Umsch; 2016; 73(5):247-52. PubMed ID: 27268447 [TBL] [Abstract][Full Text] [Related]
18. Immunogenicity, reactogenicity and safety of 2 doses of an adjuvanted herpes zoster subunit vaccine administered 2, 6 or 12 months apart in older adults: Results of a phase III, randomized, open-label, multicenter study. Lal H; Poder A; Campora L; Geeraerts B; Oostvogels L; Vanden Abeele C; Heineman TC Vaccine; 2018 Jan; 36(1):148-154. PubMed ID: 29174683 [TBL] [Abstract][Full Text] [Related]
19. Herpes zoster vaccine effectiveness and manifestations of herpes zoster and associated pain by vaccination status. Marin M; Yawn BP; Hales CM; Wollan PC; Bialek SR; Zhang J; Kurland MJ; Harpaz R Hum Vaccin Immunother; 2015; 11(5):1157-64. PubMed ID: 25806911 [TBL] [Abstract][Full Text] [Related]
20. Herpes zoster vaccination in people aged 50-59 years. Li HT; Lu S; Liu JM Clin Infect Dis; 2012 Apr; 54(7):929-30. PubMed ID: 22291102 [No Abstract] [Full Text] [Related] [Next] [New Search]